Suppr超能文献

男性生殖细胞肿瘤患者的腹膜癌:德国睾丸癌研究组(GTCSG)汇编的登记研究。

Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG).

机构信息

Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.

Department of Medicine III-Haematology/Oncology, Red Cross Hospital, Munich, Germany.

出版信息

World J Urol. 2022 Feb;40(2):355-361. doi: 10.1007/s00345-021-03905-0. Epub 2022 Jan 7.

Abstract

PURPOSE

To report on the clinical characteristics, outcome, and frequency of peritoneal carcinosis (PC) in patients with advanced germ cell tumors (GCT), a multicenter registry analysis was carried out.

METHODS

A multicenter registry analysis was conducted by the German Testicular Cancer Study Group (GTCSG) with international collaborators. Data was collected and analyzed retrospectively. Patients were eligible for inclusion if PC was diagnosed either by radiologic or histopathologic finding during the course of disease. Descriptive and explorative statistical analysis was carried out with cancer-specific survival (CSS) as primary study endpoint.

RESULTS

Collaborators from ten GCT expert centers identified 28 GCT (0.77%) patients with PC after screening approximately 3767 GCT patient files and one case was contributed from a cancer registry request. Patients were diagnosed from 1997 to 2019 at a median age of 37 years (interquartile range, 13). Two patients (7%) presented with stage I and 27 patients (93%) with synchronous metastatic disease at first diagnosis. The primary histology was seminoma in seven (27%) and non-seminoma in 21 patients (72%). PC was detected after a median of 15.3 months from primary diagnosis (range 0-177) and two consecutive treatment lines (range 0-5), respectively. The median CSS from the time of detection of PC was 10.5 months (95%Confidence Interval 0.47-1.30) associated with an overall 2-year CSS rate of 30%.

CONCLUSION

PC represents a rare tumor manifestation in GCT patients and was primarily associated with the occurrence of advanced cisplatin-refractory disease conferring to a dismal prognosis.

摘要

目的

报告晚期生殖细胞瘤(GCT)患者中腹膜癌(PC)的临床特征、结局和频率,这是一项多中心登记分析。

方法

德国睾丸癌研究组(GTCSG)与国际合作者进行了一项多中心登记分析。在疾病过程中通过影像学或组织病理学发现 PC 的患者符合纳入标准。采用描述性和探索性统计分析,以癌症特异性生存(CSS)为主要研究终点。

结果

通过筛选大约 3767 例 GCT 患者的档案,十个 GCT 专家中心的合作者确定了 28 例 PC 患者,另有 1 例来自癌症登记请求。患者的诊断时间为 1997 年至 2019 年,中位年龄为 37 岁(四分位距 13)。2 例(7%)患者为 I 期,27 例(93%)患者初诊时为同步转移性疾病。主要组织学类型为 7 例(27%)精原细胞瘤和 21 例(72%)非精原细胞瘤。PC 分别在原发诊断后中位时间 15.3 个月(范围 0-177)和连续两次治疗线(范围 0-5)被检测到。从 PC 检测到的中位 CSS 为 10.5 个月(95%置信区间 0.47-1.30),总 2 年 CSS 率为 30%。

结论

PC 是 GCT 患者中一种罕见的肿瘤表现,主要与铂类耐药晚期疾病的发生相关,预后不良。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ec7/8921103/9f16bd94cabc/345_2021_3905_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验